½ÃÀ庸°í¼­
»óǰÄÚµå
1624233

´ÜÇÙ±¸Áõ Áø´Ü ½ÃÀå ±Ô¸ð ¹× ¿¹Ãø : ¼¼°è ¹× Áö¿ª Á¡À¯À², µ¿Çâ, ¼ºÀå ±âȸ ºÐ¼® ¸®Æ÷Æ® - À¯Çüº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº°

Mononucleosis Diagnostic Market Size and Forecast, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type, End User, and Geography

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: The Insight Partners | ÆäÀÌÁö Á¤º¸: ¿µ¹® 210 Pages | ¹è¼Û¾È³» : Áï½Ã¹è¼Û

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

The Insight PartnersÀÇ ÃֽŠÁ¶»ç ¸®Æ÷Æ® '´ÜÇÙ±¸Áõ Áø´Ü ½ÃÀå ¿¹Ãø(-2031³â) : ¼¼°è ºÐ¼® - À¯Çüº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº°'¿¡ µû¸£¸é ½ÃÀåÀº 2023³â 1¾ï 5,144¸¸ ´Þ·¯¿¡¼­ ¼ºÀåÇϸç, 2031³â¿¡´Â 2¾ï 2,215¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, 2023-2031³â¿¡ CAGR 4.9%¸¦ ±â·ÏÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. û¼Ò³â Àα¸ÀÇ ³ôÀº À§Çèµµ, ´ÜÇÙ±¸Áõ¿¡ ´ëÇÑ °Ç°­ Àνİú Áö½Ä Áõ°¡´Â ´ÜÇÙ±¸Áõ Áø´Ü ½ÃÀå ±Ô¸ð È®´ë¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ±×·¯³ª ±âÁ¸ Áø´Ü °Ë»çÀÇ ³·Àº Á¤È®µµ´Â ´ÜÇÙ±¸Áõ Áø´Ü ½ÃÀåÀÇ ¼ºÀåÀ» ÀúÇØÇÏ´Â ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ´ÜÇÙ±¸Áõ Áø´ÜÀÇ ºÐÀÚÁø´ÜÇÐÀÇ ¹ßÀüÀº ÇâÈÄ ¼ö³â°£ »õ·Î¿î ´ÜÇÙ±¸Áõ Áø´Ü ½ÃÀå µ¿ÇâÀ» °¡Á®¿Ã °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ÅÃâ¾× ±âÁØÀ¸·Î´Â ºÏ¹Ì°¡ 2023³â ´ÜÇÙ±¸Áõ Áø´Ü ½ÃÀåÀ» Àå¾ÇÇß½À´Ï´Ù. ¿¹Ãø ±â°£ Áß¿¡µµ ¼¼°è ½ÃÀåÀ» µ¶Á¡ÇÒ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù. ¹Ì±¹Àº ¼¼°è ÃÖ´ë ´ÜÇÙ±¸Áõ Áø´Ü ½ÃÀåÀ̸ç, ¿¹Ãø ±â°£ Áß¿¡µµ ½ÃÀåÀ» Áö¹èÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¹Ì±¹ ´ÜÇÙ±¸Áõ Áø´Ü ½ÃÀåÀÇ ¼ºÀåÀº ±â¼ú ¹ßÀü, ÀÎ½Ä °³¼±, È¿°úÀûÀÎ Áúº´ °ü¸® Àü·«¿¡ ´ëÇÑ ²÷ÀÓ¾ø´Â ¼ö¿ä¿¡ ±âÀÎÇÕ´Ï´Ù. ¹Ì±¹ ±¹¸³º¸°Ç¿ø¿¡ µû¸£¸é ¹Ì±¹¿¡¼­´Â ¸Å³â 125,000°ÇÀÇ Àü¿°¼º ´ÜÇÙ±¸Áõ ȯÀÚ°¡ ¹ß»ýÇÕ´Ï´Ù. ÀÌ·¯ÇÑ È¯ÀÚ ¼ö·Î ÀÎÇØ ¿¦½ºÅ¸ÀÎ-¹Ù ¹ÙÀÌ·¯½º(EBV)·Î ÀÎÇÑ ´ÜÇÙ±¸Áõ¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ ½Å¼ÓÇϰí Á¤È®ÇÑ Áø´Ü Å×½ºÆ® ŰƮ, ¼Ò¸ðǰ ¹× ¼­ºñ½º¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¹Ì±¹³» ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õµéÀÌ »ç¿ëÇÏ´Â ´Ù¾çÇÑ °Ë»ç ¹æ¹ý¿¡´Â Ç×ü °ËÃâ¿¡ ±â¹ÝÇÑ Ç÷ûÇÐÀû °Ë»ç, ¹ÙÀÌ·¯½º DNA ½Äº°¿¡ ÃÊÁ¡À» ¸ÂÃá ºÐÀÚ °Ë»ç µîÀÌ ÀÖ½À´Ï´Ù. ¹Ì±¹ ´ÜÇÙ±¸Áõ Áø´Ü ½ÃÀå °æÀï ±¸µµ´Â Abbott Laboratories, Roche Diagnostics, Siemens Healthineers µîÀÌ ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ÀÌµé ±â¾÷Àº Á¦Ç° ¶óÀξ÷À» °­È­ÇÏ°í ½ÃÀå¿¡¼­ÀÇ ÀÔÁö¸¦ È®´ëÇϱâ À§ÇØ ±â¼ú Çõ½Å°ú Á¦ÈÞ¿¡ ÅõÀÚÇϰí ÀÖ½À´Ï´Ù.

´ÜÇÙ±¸Áõ Áø´Ü ½ÃÀå ºÐ¼®

POC °Ë»çÀÇ °³¹ßÀº ÇâÈÄ ½ÃÀå ±âȸ¸¦ °¡Á®¿Ã °ÍÀÔ´Ï´Ù.

ÇöÀåÁø´Ü(POC) °Ë»ç´Â ȯÀÚÀÇ Ä¡·á ÇöÀå ¶Ç´Â ±× ±Ùó¿¡¼­ ½Å¼ÓÇÑ Áø´ÜÀ» °¡´ÉÇÏ°Ô ÇÏ¿© ÀÇ·áÁøÀÌ Áï°¢ÀûÀÎ ÀÓ»óÀû ÆÇ´ÜÀ» ³»¸®°í ȯÀÚÀÇ °á°ú¸¦ °³¼±ÇÒ ¼ö ÀÖµµ·Ï ÇÕ´Ï´Ù. ±âÁ¸ ÀÓ»ó °Ë»ç´Â °á°ú°¡ ³ª¿À±â±îÁö ¸î ½Ã°£¿¡¼­ ¸çÄ¥ÀÌ °É¸®´Â °æ¿ì°¡ ¸¹¾Æ Ä¡·á°¡ Áö¿¬µÇ°Å³ª Áõ»óÀÌ ¾ÇÈ­µÉ ¼ö ÀÖ½À´Ï´Ù. ¹Ý¸é, POC °Ë»ç´Â ¸î ºÐ ¾È¿¡ °á°ú¸¦ ¾òÀ» ¼ö ÀÖÀ¸¸ç, Àû½Ã¿¡ °³ÀÔÇÒ ¼ö ÀÖ½À´Ï´Ù. Á¶±â Áø´ÜÀº ÇÕº´ÁõÀ» ÁÙÀ̰í ȯÀÚÀÇ Æí¾ÈÇÔÀ» Áõ°¡½Ãų ¼ö ÀÖÀ¸¹Ç·Î ´ÜÇÙ±¸Áõ°ú °°Àº Áúº´¿¡ ÀÖÀ¸¸ç, ½Å¼ÓÇÑ °á°ú´Â ƯÈ÷ Áß¿äÇϸç, POC °Ë»ç´Â ¿Ü·¡ Áø·á¼Ò, ÀÀ±Þ½Ç, ÀçÅà ġ·á µî ´Ù¾çÇÑ ÀÇ·á ȯ°æ¿¡¼­ ½ÃÇàÇÒ ¼ö ÀÖ½À´Ï´Ù. °Ë»ç ÀÎÇÁ¶ó°¡ Á¦ÇÑÀûÀÎ Áö¿ªÀ̳ª ÀÇ·á ÀÚ¿øÀÌ ºÎÁ·ÇÑ Áö¹æ¿¡¼­´Â Á¢±Ù¼ºÀÌ Æ¯È÷ À¯¿ëÇϸç, POC °Ë»çÀÇ ÇüÅ·ΠÁø´Ü ´É·ÂÀ» ȯÀÚ¿¡°Ô ´õ °¡±îÀÌ °¡Á®¿Í ´õ ¸¹Àº »ç¶÷µéÀÌ Àû½Ã¿¡ Áø´Ü°ú ÀûÀýÇÑ Ä¡·á¸¦ ¹ÞÀ» ¼ö ÀÖÀ¸¸ç, ÀÇ·á ¼­ºñ½ºÀÇ ¹üÀ§¸¦ ³ÐÈú ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÀÌ·¯ÇÑ À¯ÇüÀÇ Å×½ºÆ®´Â ȯÀÚ°¡ ½Å¼ÓÇÏ°Ô °á°ú¸¦ ¹Þ°í ´ÙÀ½ ´Ü°è¿¡ ´ëÇØ ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ¿Í ³íÀÇÇÒ ¼ö ÀÖÀ¸¹Ç·Î ´õ ¸¹Àº Âü¿©¸¦ ÃËÁøÇÕ´Ï´Ù.

POC °Ë»ç´Â ´ë±Ô¸ð °Ë»ç ÀÎÇÁ¶ó¸¦ ÇÊ¿ä·Î ÇÏÁö ¾Ê±â ¶§¹®¿¡ ±âÁ¸ °Ë»ç½Ç °Ë»ç¿¡ ºñÇØ ºñ¿ë È¿À²ÀûÀ̸ç, °á°úÀûÀ¸·Î Àüü ÀÇ·á ½Ã½ºÅÛ ºñ¿ëÀ» ³·Ãâ ¼ö ÀÖ½À´Ï´Ù. ´ÜÇÙ±¸Áõ °Ë»çÀÇ Àú·ÅÇÑ °¡°ÝÀº ƯÈ÷ ÀÇ·á ¼­ºñ½º¸¦ ÃæºÐÈ÷ ¹ÞÁö ¸øÇϴ ȯÀÚÃþ µî º¸´Ù ±¤¹üÀ§ÇÑ È¯ÀÚ Á¢±Ù¼ºÀ» ´õ¿í ÃËÁøÇÒ ¼ö ÀÖ½À´Ï´Ù. ÃÖ±Ù ¹ÙÀÌ¿À¼¾¼­ ¹× ¸¶ÀÌÅ©·ÎÇ÷çÀ̵ñ½º ±â¼úÀÇ ¹ßÀüÀ¸·Î ¹Î°¨µµ¿Í ƯÀ̵µ°¡ Çâ»óµÈ º¸´Ù Á¤±³ÇÑ ÇöÀåÁø´Ü(POC) °Ë»çÀÇ °³¹ßÀÌ °¡¼ÓÈ­µÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú Çõ½ÅÀº ´ÜÇÙ±¸Áõ °ËÃâ¿¡ ÀÖÀ¸¸ç, POC °Ë»çÀÇ ½Å·Ú¼ºÀ» º¸ÀåÇϰí ÀÖÀ¸¸ç, POC °Ë»ç ŰƮ¸¦ Á¦°øÇÏ´Â ´ÜÇÙ±¸Áõ Áø´Ü ½ÃÀå ±â¾÷À¸·Î´Â SEKISUI Diagnostics(OSOM Mono Test), Abbott(Clearview Mono), Cardinal Health(Cardinal Health) µîÀÌ ÀÖ½À´Ï´Ù. Cardinal Health(Cardinal Health MONO(Mononucleosis) II Rapid Test) µîÀÌ ÀÖ½À´Ï´Ù. ÀÌó·³ POC °Ë»çÀÇ °³¹ßÀº ´ÜÇÙ±¸Áõ Áø´Ü ½ÃÀåÀÇ ±â¾÷¿¡°Ô ½ÇÁúÀûÀÎ ¼ºÀå ±âȸ¸¦ âÃâÇϰí ÀÖ½À´Ï´Ù.

´ÜÇÙ±¸Áõ Áø´Ü ½ÃÀå º¸°í¼­ ¼¼ºÐÈ­ ºÐ¼®

´ÜÇÙ±¸Áõ Áø´Ü ½ÃÀåÀÇ ºÐ¼®¿¡ ±â¿©ÇÑ ÁÖ¿ä ºÎ¹®Àº À¯Çü ¹× ÃÖÁ¾»ç¿ëÀÚÀÔ´Ï´Ù.

À¯Çüº°·Î ´ÜÇÙ±¸Áõ Áø´Ü ½ÃÀåÀº ¾Û½ºÅ¸ÀÎ ¹Ù ¹ÙÀÌ·¯½º Ç×ü °Ë»ç, ÀüÇ÷±¸ °è»ê °Ë»ç, ¸ð³ë½ºÆÌ °Ë»ç·Î ±¸ºÐµÇ¸ç, 2023³â ´ÜÇÙ±¸Áõ Áø´Ü ½ÃÀåÀº ¸ð³ë½ºÆÌ °Ë»ç ºÎ¹®ÀÌ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÃÖÁ¾»ç¿ëÀÚº°·Î ´ÜÇÙ±¸Áõ Áø´Ü ½ÃÀåÀº º´¿ø, ¿¬±¸¼Ò, ±âŸ·Î ºÐ·ùµÇ¸ç, 2023³â¿¡´Â º´¿ø ºÎ¹®ÀÌ ½ÃÀåÀ» Àå¾ÇÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

´ÜÇÙ±¸Áõ Áø´Ü ½ÃÀå °æÀï ±¸µµ ¹× ÁÖ¿ä ¹ßÀü »óȲ

Abbott Laboratories, Arlington Scientific Inc, Bio-Rad Laboratories Inc, Cardinal Health Inc, Meridian Bioscience Inc, Sekisui Diagnostics LLC, Thermo Fisher Scientific Inc, QuidelOrtho Corp, F. Hoffmann-La Roche Ltd, QIAGEN NV, Hologic Inc, bioMerieux SA, DiaSorin SpA, Immunostics Inc, Launch Diagnostics Ltd, Biorex Diagnostics, ZEUS ScientificÀº ´ÜÇÙ±¸Áõ Áø´Ü ½ÃÀå¿¡¼­ »ç¾÷À» µµÀÔÇϰí ÀÖ´Â ÁÖ¿ä ±â¾÷ÀÔ´Ï´Ù.

À¯¿£¾Æµ¿±â±Ý(UNICEF), ±¹¸³ÀÇÇеµ¼­°ü, Áúº´ÅëÁ¦¿¹¹æ¼¾ÅÍ(CDC), ±¹¸³º¸°Ç¿ø, ij³ª´Ù Åë°èû, ¿¬¹æÅë°èû(Destatis) µîÀº ´ÜÇÙ±¸Áõ Áø´Ü ½ÃÀå º¸°í¼­ ÀÛ¼º½Ã Âü°íÇÑ 1Â÷ ¹× 2Â÷ Á¤º¸ÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­·Ð

Á¦2Àå °³¿ä

  • ÁÖ¿ä ÀλçÀÌÆ®

Á¦3Àå Á¶»ç ¹æ¹ý

  • 2Â÷ Á¶»ç
  • 1Â÷ Á¶»ç
    • °¡¼³ Ã¥Á¤
    • °Å½Ã°æÁ¦ ¿äÀÎ ºÐ¼®
    • ±âÃÊ ¼öÄ¡ÀÇ °³¹ß
    • µ¥ÀÌÅÍ »ï°¢Ãø·®
    • ±¹°¡ ·¹º§ µ¥ÀÌÅÍ

Á¦4Àå ´ÜÇÙ±¸Áõ Áø´Ü ½ÃÀå ±¸µµ

  • PEST ºÐ¼®

Á¦5Àå ´ÜÇÙ±¸Áõ Áø´Ü ½ÃÀå - ÁÖ¿ä ½ÃÀå ¿ªÇÐ

  • ´ÜÇÙ±¸Áõ Áø´Ü ½ÃÀå - ÁÖ¿ä ½ÃÀå ¿ªÇÐ
  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • û¼Ò³âÃþ¿¡¼­ÀÇ ÇÏÀ̸®½ºÅ©
    • ´ÜÇÙ±¸Áõ¿¡ °üÇÑ °Ç°­ Àǽİú Áö½ÄÀÇ Áõ°¡
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ±âÁ¸ Áø´Ü °Ë»çÀÇ ³·Àº Á¤µµ
  • ½ÃÀå ±âȸ
    • POC(Point of Care) °Ë»çÀÇ °³¹ß
  • ÇâÈÄ µ¿Çâ
    • ºÐÀÚÁø´ÜÇÐÀÇ Áøº¸
  • ÃËÁø¿äÀΰú ¾ïÁ¦¿äÀÎÀÇ ¿µÇâ

Á¦6Àå ´ÜÇÙ±¸Áõ Áø´Ü ½ÃÀå : ¼¼°è ½ÃÀå ºÐ¼®

  • ´ÜÇÙ±¸Áõ Áø´Ü ½ÃÀå ¸ÅÃâ, 2021-2031³â
  • ´ÜÇÙ±¸Áõ Áø´Ü ½ÃÀå ¿¹Ãø ºÐ¼®

Á¦7Àå ´ÜÇÙ±¸Áõ Áø´Ü ½ÃÀå ºÐ¼® - À¯Çüº°

  • Monospot Test
  • Epstein Barr Virus Ç×ü °Ë»ç
  • ÀüÇ÷±¸¼ö°Ë»ç

Á¦8Àå ´ÜÇÙ±¸Áõ Áø´Ü ½ÃÀå ºÐ¼® - ÃÖÁ¾»ç¿ëÀÚº°

  • º´¿ø
  • ¿¬±¸¼Ò
  • ±âŸ

Á¦9Àå ´ÜÇÙ±¸Áõ Áø´Ü ½ÃÀå ºÐ¼® - Áö¿ªº°

  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
    • ¸ß½ÃÄÚ
  • À¯·´
    • µ¶ÀÏ
    • ¿µ±¹
    • ÇÁ¶û½º
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • ÀϺ»
    • Àεµ
    • È£ÁÖ
    • Çѱ¹
    • ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ±âŸ ±¹°¡
  • Áß³²¹Ì
    • ºê¶óÁú
    • ¾Æ¸£ÇîÆ¼³ª
    • ±âŸ Áß³²¹Ì
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • ¾Æ¶ø¿¡¹Ì¸®Æ®
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦10Àå ¾÷°è »óȲ

  • ´ÜÇÙ±¸Áõ Áø´Ü ½ÃÀå¿¡¼­ÀÇ ¼ºÀå Àü·«
  • À¯±âÀû ¼ºÀå Àü·«
  • ¹«±âÀû ¼ºÀå Àü·«

Á¦11Àå ±â¾÷ °³¿ä

  • Abbott Laboratories
  • Arlington Scientific Inc
  • Bio-Rad Laboratories Inc
  • Cardinal Health Inc
  • Meridian Bioscience Inc
  • Sekisui Diagnostics LLC
  • Thermo Fisher Scientific Inc
  • QuidelOrtho Corp
  • F. Hoffmann-La Roche Ltd
  • QIAGEN NV
  • Hologic Inc
  • bioMerieux SA
  • DiaSorin SpA
  • Immunostics Inc.
  • Launch Diagnostics Ltd
  • Biorex Diagnostics
  • ZEUS Scientific

Á¦12Àå ºÎ·Ï

KSA 25.02.05

According to our new research study on "Mononucleosis Diagnostic Market Forecast to 2031 -Global Analysis - by Type, End User, and Geography," the market is anticipated to grow from US$ 151.44 million in 2023 and is projected to reach US$ 222.15 million by 2031; it is expected to register a CAGR of 4.9% during 2023-2031. High risk among the adolescent population, and the rising health awareness and knowledge about mononucleosis are contributing to the growing mononucleosis diagnostic market size. However, the low accuracy of existing diagnostic tests hampers the mononucleosis diagnostic market growth. Further, advancements in molecular diagnostics in mononucleosis diagnostic are expected to bring in new mononucleosis diagnostic market trends in the coming years.

In terms of revenue, North America dominated the mononucleosis diagnostic market in 2023. It is estimated to dominate the global market during the forecast period. The US is the largest market for mononucleosis diagnostics in the world, and it is estimated to dominate the market during the forecast period as well. The mononucleosis diagnostic market growth in the US is attributed to technological advancements, increased awareness, and a constant need for effective disease management strategies. According to the National Institutes of Health, the US records ~125,000 cases of infectious mononucleosis every year. Owing to such a high number, the awareness of the mononucleosis caused by the Epstein-Barr virus (EBV) is also on the rise in the country, which bolsters the demand for rapid and accurate diagnostic test kits, consumables, and services. Various testing methods adopted by healthcare providers in the country include serological tests based on antibody detection and molecular tests focused on viral DNA identification. The competitive landscape of the mononucleosis diagnostics market in the US is dominated by companies such as Abbott Laboratories, Roche Diagnostics, and Siemens Healthineers. These companies invest in innovation and collaborations to enhance their product offerings and expand their market presence.

Mononucleosis Diagnostic Market Analysis

Development of Point-of-Care Testing to Provide Market Opportunities in Future

POC testing allows for rapid diagnosis at or near the site of patient care, enabling healthcare providers to make immediate clinical decisions and improve patient outcomes. Traditional laboratory tests often require hours or days to generate results, which can delay treatment and worsen symptoms. In contrast, POC tests can deliver results within minutes, facilitating timely intervention. The rapid turnaround is especially crucial for conditions such as mononucleosis, as early diagnosis can reduce complications and enhance patient comfort. POC testing can be implemented in various healthcare settings, including outpatient clinics, emergency departments, and home care settings. The accessibility is particularly beneficial in areas with limited laboratory infrastructure or in rural regions with insufficient healthcare resources. Bringing diagnostic capabilities closer to patients in the form of POC testing ensures that more individuals receive timely diagnoses and appropriate care, thereby broadening the reach of healthcare services. Moreover, this type of testing promotes greater engagement, as patients can receive their results quickly and discuss the next steps with their healthcare providers.

POC testing can be more cost-effective compared to traditional laboratory testing as they don't need extensive laboratory infrastructure, in turn lowering the overall costs for healthcare systems. The affordability of mononucleosis testing further drives its accessibility to a broader range of patients, especially in underserved populations. Recent advancements in biosensors and microfluidic technologies are driving the development of more sophisticated POC tests with improved sensitivity and specificity. These innovations ensure the reliability of POC tests in detecting mononucleosis. Mononucleosis diagnostic market players offering POC test kits include SEKISUI Diagnostics (OSOM Mono Test), Abbott (Clearview Mono), and Cardinal Health [Cardinal Health MONO (Mononucleosis) II Rapid Test]. Thus, the development of POC testing generates substantial growth opportunities for the mononucleosis diagnostics market players.

Mononucleosis Diagnostic Market Report Segmentation Analysis

Key segments that contributed to the derivation of the mononucleosis diagnostic market analysis are type and end user.

Based on type, the mononucleosis diagnostic market is segmented into Epstein Barr Virus antibody test, complete blood count test, and monospot test. The monospot test segment held the largest mononucleosis diagnostic market share of the market in 2023.

In terms of end user, the mononucleosis diagnostic market is categorized into hospitals, laboratories, and others. The hospitals segment dominated the market in 2023.

Mononucleosis Diagnostic Market: Competitive Landscape and Key Developments

Abbott Laboratories, Arlington Scientific Inc, Bio-Rad Laboratories Inc, Cardinal Health Inc, Meridian Bioscience Inc, Sekisui Diagnostics LLC, Thermo Fisher Scientific Inc, QuidelOrtho Corp, F. Hoffmann-La Roche Ltd, QIAGEN NV, Hologic Inc, bioMerieux SA, DiaSorin SpA, Immunostics Inc., Launch Diagnostics Ltd, Biorex Diagnostics, and ZEUS Scientific are among the key companies operating in the mononucleosis diagnostic market.

The United Nations Children's Fund (UNICEF), National Library of Medicine, Centers for Disease Control and Prevention (CDC), National Institutes of Health, Statistics Canada, Federal Statistical Office (Destatis) are among the primary and secondary sources referred to while preparing the mononucleosis diagnostic market report.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Secondary Research
  • 3.2 Primary Research
    • 3.2.1 Hypothesis formulation:
    • 3.2.2 Macro-economic factor analysis:
    • 3.2.3 Developing base number:
    • 3.2.4 Data Triangulation:
    • 3.2.5 Country level data:

4. Mononucleosis Diagnostics Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis

5. Mononucleosis Diagnostics Market - Key Market Dynamics

  • 5.1 Mononucleosis Diagnostics Market - Key Market Dynamics
  • 5.2 Market Drivers
    • 5.2.1 High Risk among Adolescent Population
    • 5.2.2 Rising Health Awareness and Knowledge About Mononucleosis
  • 5.3 Market Restraints
    • 5.3.1 Low Accuracy of Existing Diagnostic Tests
  • 5.4 Market Opportunities
    • 5.4.1 Development of Point-of-Care Testing
  • 5.5 Future Trends
    • 5.5.1 Advancements in Molecular Diagnostics
  • 5.6 Impact of Drivers and Restraints:

6. Mononucleosis Diagnostics Market - Global Market Analysis

  • 6.1 Mononucleosis Diagnostics Market Revenue (US$ Thousand), 2021-2031
  • 6.2 Mononucleosis Diagnostics Market Forecast Analysis

7. Mononucleosis Diagnostics Market Analysis - by Type

  • 7.1 Monospot Test
    • 7.1.1 Overview
    • 7.1.2 Monospot Test: Mononucleosis Diagnostics Market - Revenue and Forecast to 2031 (US$ Thousand)
  • 7.2 Epstein Barr Virus Antibody Test
    • 7.2.1 Overview
    • 7.2.2 Epstein Barr Virus Antibody Test: Mononucleosis Diagnostics Market - Revenue and Forecast to 2031 (US$ Thousand)
  • 7.3 Complete Blood Count Test
    • 7.3.1 Overview
    • 7.3.2 Complete Blood Count Test: Mononucleosis Diagnostics Market - Revenue and Forecast to 2031 (US$ Thousand)

8. Mononucleosis Diagnostics Market Analysis - by End User

  • 8.1 Hospital
    • 8.1.1 Overview
    • 8.1.2 Hospital: Mononucleosis Diagnostics Market - Revenue and Forecast to 2031 (US$ Thousand)
  • 8.2 Laboratories
    • 8.2.1 Overview
    • 8.2.2 Laboratories: Mononucleosis Diagnostics Market - Revenue and Forecast to 2031 (US$ Thousand)
  • 8.3 Others
    • 8.3.1 Overview
    • 8.3.2 Others: Mononucleosis Diagnostics Market - Revenue and Forecast to 2031 (US$ Thousand)

9. Mononucleosis Diagnostics Market - Geographical Analysis

  • 9.1 North America
    • 9.1.1 North America Mononucleosis Diagnostics Market Overview
    • 9.1.2 North America: Mononucleosis Diagnostics Market - Revenue and Forecast to 2031 (US$ Thousand)
    • 9.1.3 North America: Mononucleosis Diagnostics Market Breakdown, by Type
      • 9.1.3.1 North America: Mononucleosis Diagnostics Market - Revenue and Forecast Analysis - by Type
    • 9.1.4 North America: Mononucleosis Diagnostics Market Breakdown, by End User
      • 9.1.4.1 North America: Mononucleosis Diagnostics Market - Revenue and Forecast Analysis - by End User
    • 9.1.5 North America: Mononucleosis Diagnostics Market - Revenue and Forecast Analysis - by Country
      • 9.1.5.1 United States: Mononucleosis Diagnostics Market - Revenue and Forecast to 2031 (US$ Thousand)
        • 9.1.5.1.1 United States: Mononucleosis Diagnostics Market Breakdown, by Type
        • 9.1.5.1.2 United States: Mononucleosis Diagnostics Market Breakdown, by End User
      • 9.1.5.2 Canada: Mononucleosis Diagnostics Market - Revenue and Forecast to 2031 (US$ Thousand)
        • 9.1.5.2.1 Canada: Mononucleosis Diagnostics Market Breakdown, by Type
        • 9.1.5.2.2 Canada: Mononucleosis Diagnostics Market Breakdown, by End User
      • 9.1.5.3 Mexico: Mononucleosis Diagnostics Market - Revenue and Forecast to 2031 (US$ Thousand)
        • 9.1.5.3.1 Mexico: Mononucleosis Diagnostics Market Breakdown, by Type
        • 9.1.5.3.2 Mexico: Mononucleosis Diagnostics Market Breakdown, by End User
  • 9.2 Europe
    • 9.2.1 Europe Mononucleosis Diagnostics Market Overview
    • 9.2.2 Europe: Mononucleosis Diagnostics Market - Revenue and Forecast to 2031 (US$ Thousand)
      • 9.2.2.1 Europe: Mononucleosis Diagnostics Market - Revenue and Forecast Analysis - by Type
      • 9.2.2.2 Europe: Mononucleosis Diagnostics Market - Revenue and Forecast Analysis - by End User
    • 9.2.3 Europe: Mononucleosis Diagnostics Market - Revenue and Forecast Analysis - by Country
      • 9.2.3.1 Germany: Mononucleosis Diagnostics Market - Revenue and Forecast to 2031 (US$ Thousand)
        • 9.2.3.1.1 Germany: Mononucleosis Diagnostics Market Breakdown, by Type
        • 9.2.3.1.2 Germany: Mononucleosis Diagnostics Market Breakdown, by End User
      • 9.2.3.2 United Kingdom: Mononucleosis Diagnostics Market - Revenue and Forecast to 2031 (US$ Thousand)
        • 9.2.3.2.1 United Kingdom: Mononucleosis Diagnostics Market Breakdown, by Type
        • 9.2.3.2.2 United Kingdom: Mononucleosis Diagnostics Market Breakdown, by End User
      • 9.2.3.3 France: Mononucleosis Diagnostics Market - Revenue and Forecast to 2031 (US$ Thousand)
        • 9.2.3.3.1 France: Mononucleosis Diagnostics Market Breakdown, by Type
        • 9.2.3.3.2 France: Mononucleosis Diagnostics Market Breakdown, by End User
      • 9.2.3.4 Italy: Mononucleosis Diagnostics Market - Revenue and Forecast to 2031 (US$ Thousand)
        • 9.2.3.4.1 Italy: Mononucleosis Diagnostics Market Breakdown, by Type
        • 9.2.3.4.2 Italy: Mononucleosis Diagnostics Market Breakdown, by End User
      • 9.2.3.5 Spain: Mononucleosis Diagnostics Market - Revenue and Forecast to 2031 (US$ Thousand)
        • 9.2.3.5.1 Spain: Mononucleosis Diagnostics Market Breakdown, by Type
        • 9.2.3.5.2 Spain: Mononucleosis Diagnostics Market Breakdown, by End User
      • 9.2.3.6 Rest of Europe: Mononucleosis Diagnostics Market - Revenue and Forecast to 2031 (US$ Thousand)
        • 9.2.3.6.1 Rest of Europe: Mononucleosis Diagnostics Market Breakdown, by Type
        • 9.2.3.6.2 Rest of Europe: Mononucleosis Diagnostics Market Breakdown, by End User
  • 9.3 Asia Pacific
    • 9.3.1 Asia Pacific Mononucleosis Diagnostics Market Overview
    • 9.3.2 Asia Pacific: Mononucleosis Diagnostics Market - Revenue and Forecast to 2031 (US$ Thousand)
      • 9.3.2.1 Asia Pacific: Mononucleosis Diagnostics Market - Revenue and Forecast Analysis - by Type
      • 9.3.2.2 Asia Pacific: Mononucleosis Diagnostics Market - Revenue and Forecast Analysis - by End User
    • 9.3.3 Asia Pacific: Mononucleosis Diagnostics Market - Revenue and Forecast Analysis - by Country
      • 9.3.3.1 China: Mononucleosis Diagnostics Market - Revenue and Forecast to 2031 (US$ Thousand)
        • 9.3.3.1.1 China: Mononucleosis Diagnostics Market Breakdown, by Type
        • 9.3.3.1.2 China: Mononucleosis Diagnostics Market Breakdown, by End User
      • 9.3.3.2 Japan: Mononucleosis Diagnostics Market - Revenue and Forecast to 2031 (US$ Thousand)
        • 9.3.3.2.1 Japan: Mononucleosis Diagnostics Market Breakdown, by Type
        • 9.3.3.2.2 Japan: Mononucleosis Diagnostics Market Breakdown, by End User
      • 9.3.3.3 India: Mononucleosis Diagnostics Market - Revenue and Forecast to 2031 (US$ Thousand)
        • 9.3.3.3.1 India: Mononucleosis Diagnostics Market Breakdown, by Type
        • 9.3.3.3.2 India: Mononucleosis Diagnostics Market Breakdown, by End User
      • 9.3.3.4 Australia: Mononucleosis Diagnostics Market - Revenue and Forecast to 2031 (US$ Thousand)
        • 9.3.3.4.1 Australia: Mononucleosis Diagnostics Market Breakdown, by Type
        • 9.3.3.4.2 Australia: Mononucleosis Diagnostics Market Breakdown, by End User
      • 9.3.3.5 South Korea: Mononucleosis Diagnostics Market - Revenue and Forecast to 2031 (US$ Thousand)
        • 9.3.3.5.1 South Korea: Mononucleosis Diagnostics Market Breakdown, by Type
        • 9.3.3.5.2 South Korea: Mononucleosis Diagnostics Market Breakdown, by End User
      • 9.3.3.6 Rest of APAC: Mononucleosis Diagnostics Market - Revenue and Forecast to 2031 (US$ Thousand)
        • 9.3.3.6.1 Rest of APAC: Mononucleosis Diagnostics Market Breakdown, by Type
        • 9.3.3.6.2 Rest of APAC: Mononucleosis Diagnostics Market Breakdown, by End User
  • 9.4 South and Central America
    • 9.4.1 South and Central America Mononucleosis Diagnostics Market Overview
    • 9.4.2 South and Central America: Mononucleosis Diagnostics Market - Revenue and Forecast to 2031 (US$ Thousand)
      • 9.4.2.1 South and Central America: Mononucleosis Diagnostics Market - Revenue and Forecast Analysis - by Type
      • 9.4.2.2 South and Central America: Mononucleosis Diagnostics Market - Revenue and Forecast Analysis - by End User
    • 9.4.3 South and Central America: Mononucleosis Diagnostics Market - Revenue and Forecast Analysis - by Country
      • 9.4.3.1 Brazil: Mononucleosis Diagnostics Market - Revenue and Forecast to 2031 (US$ Thousand)
        • 9.4.3.1.1 Brazil: Mononucleosis Diagnostics Market Breakdown, by Type
        • 9.4.3.1.2 Brazil: Mononucleosis Diagnostics Market Breakdown, by End User
      • 9.4.3.2 Argentina: Mononucleosis Diagnostics Market - Revenue and Forecast to 2031 (US$ Thousand)
        • 9.4.3.2.1 Argentina: Mononucleosis Diagnostics Market Breakdown, by Type
        • 9.4.3.2.2 Argentina: Mononucleosis Diagnostics Market Breakdown, by End User
      • 9.4.3.3 Rest of South and Central America: Mononucleosis Diagnostics Market - Revenue and Forecast to 2031 (US$ Thousand)
        • 9.4.3.3.1 Rest of South and Central America: Mononucleosis Diagnostics Market Breakdown, by Type
        • 9.4.3.3.2 Rest of South and Central America: Mononucleosis Diagnostics Market Breakdown, by End User
  • 9.5 Middle East and Africa
    • 9.5.1 Middle East and Africa Mononucleosis Diagnostics Market Overview
    • 9.5.2 Middle East and Africa: Mononucleosis Diagnostics Market - Revenue and Forecast to 2031 (US$ Thousand)
      • 9.5.2.1 Middle East and Africa: Mononucleosis Diagnostics Market - Revenue and Forecast Analysis - by Type
      • 9.5.2.2 Middle East and Africa: Mononucleosis Diagnostics Market - Revenue and Forecast Analysis - by End User
    • 9.5.3 Middle East and Africa: Mononucleosis Diagnostics Market - Revenue and Forecast Analysis - by Country
      • 9.5.3.1 Middle East and Africa: Mononucleosis Diagnostics Market - Revenue and Forecast Analysis - by Country
      • 9.5.3.2 Saudi Arabia: Mononucleosis Diagnostics Market - Revenue and Forecast to 2031 (US$ Thousand)
        • 9.5.3.2.1 Saudi Arabia: Mononucleosis Diagnostics Market Breakdown, by Type
        • 9.5.3.2.2 Saudi Arabia: Mononucleosis Diagnostics Market Breakdown, by End User
      • 9.5.3.3 South Africa: Mononucleosis Diagnostics Market - Revenue and Forecast to 2031 (US$ Thousand)
        • 9.5.3.3.1 South Africa: Mononucleosis Diagnostics Market Breakdown, by Type
        • 9.5.3.3.2 South Africa: Mononucleosis Diagnostics Market Breakdown, by End User
      • 9.5.3.4 United Arab Emirates: Mononucleosis Diagnostics Market - Revenue and Forecast to 2031 (US$ Thousand)
        • 9.5.3.4.1 United Arab Emirates: Mononucleosis Diagnostics Market Breakdown, by Type
        • 9.5.3.4.2 United Arab Emirates: Mononucleosis Diagnostics Market Breakdown, by End User
      • 9.5.3.5 Rest of Middle East and Africa: Mononucleosis Diagnostics Market - Revenue and Forecast to 2031 (US$ Thousand)
        • 9.5.3.5.1 Rest of Middle East and Africa: Mononucleosis Diagnostics Market Breakdown, by Type
        • 9.5.3.5.2 Rest of Middle East and Africa: Mononucleosis Diagnostics Market Breakdown, by End User

10. Industry Landscape

  • 10.1 Overview
  • 10.2 Growth Strategies in Mononucleosis Diagnostic Market
  • 10.3 Organic Growth Strategies
    • 10.3.1 Overview
  • 10.4 Inorganic Growth Strategies
    • 10.4.1 Overview

11. Company Profiles

  • 11.1 Abbott Laboratories
    • 11.1.1 Key Facts
    • 11.1.2 Business Description
    • 11.1.3 Products and Services
    • 11.1.4 Financial Overview
    • 11.1.5 SWOT Analysis
    • 11.1.6 Key Developments
  • 11.2 Arlington Scientific Inc
    • 11.2.1 Key Facts
    • 11.2.2 Business Description
    • 11.2.3 Products and Services
    • 11.2.4 Financial Overview
    • 11.2.5 SWOT Analysis
    • 11.2.6 Key Developments
  • 11.3 Bio-Rad Laboratories Inc
    • 11.3.1 Key Facts
    • 11.3.2 Business Description
    • 11.3.3 Products and Services
    • 11.3.4 Financial Overview
    • 11.3.5 SWOT Analysis
    • 11.3.6 Key Developments
  • 11.4 Cardinal Health Inc
    • 11.4.1 Key Facts
    • 11.4.2 Business Description
    • 11.4.3 Products and Services
    • 11.4.4 Financial Overview
    • 11.4.5 SWOT Analysis
    • 11.4.6 Key Developments
  • 11.5 Meridian Bioscience Inc
    • 11.5.1 Key Facts
    • 11.5.2 Business Description
    • 11.5.3 Products and Services
    • 11.5.4 Financial Overview
    • 11.5.5 SWOT Analysis
    • 11.5.6 Key Developments
  • 11.6 Sekisui Diagnostics LLC
    • 11.6.1 Key Facts
    • 11.6.2 Business Description
    • 11.6.3 Products and Services
    • 11.6.4 Financial Overview
    • 11.6.5 SWOT Analysis
    • 11.6.6 Key Developments
  • 11.7 Thermo Fisher Scientific Inc
    • 11.7.1 Key Facts
    • 11.7.2 Business Description
    • 11.7.3 Products and Services
    • 11.7.4 Financial Overview
    • 11.7.5 SWOT Analysis
    • 11.7.6 Key Developments
  • 11.8 QuidelOrtho Corp
    • 11.8.1 Key Facts
    • 11.8.2 Business Description
    • 11.8.3 Products and Services
    • 11.8.4 Financial Overview
    • 11.8.5 SWOT Analysis
    • 11.8.6 Key Developments
  • 11.9 F. Hoffmann-La Roche Ltd
    • 11.9.1 Key Facts
    • 11.9.2 Business Description
    • 11.9.3 Products and Services
    • 11.9.4 Financial Overview
    • 11.9.5 SWOT Analysis
    • 11.9.6 Key Developments
  • 11.10 QIAGEN NV
    • 11.10.1 Key Facts
    • 11.10.2 Business Description
    • 11.10.3 Products and Services
    • 11.10.4 Financial Overview
    • 11.10.5 SWOT Analysis
    • 11.10.6 Key Developments
  • 11.11 Hologic Inc
    • 11.11.1 Key Facts
    • 11.11.2 Business Description
    • 11.11.3 Products and Services
    • 11.11.4 Financial Overview
    • 11.11.5 SWOT Analysis
    • 11.11.6 Key Developments
  • 11.12 bioMerieux SA
    • 11.12.1 Key Facts
    • 11.12.2 Business Description
    • 11.12.3 Products and Services
    • 11.12.4 Financial Overview
    • 11.12.5 SWOT Analysis
    • 11.12.6 Key Developments
  • 11.13 DiaSorin SpA
    • 11.13.1 Key Facts
    • 11.13.2 Business Description
    • 11.13.3 Products and Services
    • 11.13.4 Financial Overview
    • 11.13.5 SWOT Analysis
    • 11.13.6 Key Developments
  • 11.14 Immunostics Inc.
    • 11.14.1 Key Facts
    • 11.14.2 Business Description
    • 11.14.3 Products and Services
    • 11.14.4 Financial Overview
    • 11.14.5 SWOT Analysis
    • 11.14.6 Key Developments
  • 11.15 Launch Diagnostics Ltd
    • 11.15.1 Key Facts
    • 11.15.2 Business Description
    • 11.15.3 Products and Services
    • 11.15.4 Financial Overview
    • 11.15.5 SWOT Analysis
    • 11.15.6 Key Developments
  • 11.16 Biorex Diagnostics
    • 11.16.1 Key Facts
    • 11.16.2 Business Description
    • 11.16.3 Products and Services
    • 11.16.4 Financial Overview
    • 11.16.5 SWOT Analysis
    • 11.16.6 Key Developments
  • 11.17 ZEUS Scientific
    • 11.17.1 Key Facts
    • 11.17.2 Business Description
    • 11.17.3 Products and Services
    • 11.17.4 Financial Overview
    • 11.17.5 SWOT Analysis
    • 11.17.6 Key Developments

12. Appendix

  • 12.1 About the Insight Partners
  • 12.2 Glossary of Terms for Mononucleosis Diagnostics Market
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦